Viome Is Partnering with Henry Schein to Provide Better Access to Oral Health Pro™ With CancerDetect™
- None.
- None.
Insights
The partnership between Viome and Henry Schein to distribute the Oral Health Pro™ With CancerDetect™ test represents a significant development in the field of personalized healthcare and early cancer detection. The integration of this test into dental and medical practices could potentially lead to earlier identification of oral and throat cancers, which is critical given the high incidence rate reported in the U.S. This could translate into better patient outcomes and may also have a ripple effect on healthcare costs, as early detection often correlates with less invasive treatment and lower overall treatment costs.
From a medical research perspective, the adoption of laboratory-developed tests like Viome's, which have not been reviewed by the FDA, raises important considerations regarding clinical validation and the balance between innovation and regulation. While CLIA validation underscores the test's operational accuracy within a laboratory setting, the absence of FDA review means that broader claims about clinical efficacy and utility are not yet established by the highest regulatory standards. Stakeholders should monitor post-market performance and patient outcomes to assess the test's real-world impact.
Henry Schein's move to incorporate Viome's technology into its product offerings could strategically position the company at the forefront of preventive oral healthcare. This collaboration aligns with the broader industry trend towards preventive care models and patient-centric solutions. By being the primary distributor for this test, Henry Schein not only expands its portfolio but also potentially enhances its reputation as an innovator in dental and medical supplies.
In the long term, if the test gains traction and demonstrates clinical utility, it could stimulate demand for similar diagnostic tools, influencing research and development investments across the sector. However, it is also important to consider market dynamics, including competition from other diagnostic technologies and potential barriers to adoption such as cost, insurance coverage and clinician training. The financial impact on Henry Schein will likely depend on the test's market penetration and how it influences the company's overall sales mix.
For investors, the partnership between Viome and Henry Schein is a development that could have material implications for Henry Schein's financial performance. The key factors to watch include the test's adoption rate within dental and medical practices, its contribution to Henry Schein's revenue growth and any potential impact on profit margins. It is also essential to track how this product fits into Henry Schein's overall growth strategy and whether it can drive cross-selling opportunities within their existing customer base.
Investors should also be aware of the risks associated with the commercialization of new medical technologies, such as potential regulatory changes, market acceptance and competition. While the introduction of the Oral Health Pro™ With CancerDetect™ test could be a positive differentiator for Henry Schein in the near term, the long-term success will depend on sustained clinical validation and market adoption.
Henry Schein to Maximize Viome's Reach Among Dental and Medical Practices With Patient-Centric and Preventive Models of Care
Henry Schein will be the first stop for clinicians who want to order Oral Health Pro™ With CancerDetect™, for their patients, and will provide access to the test. After the healthcare professionals have captured a saliva sample, they will send the sample to Viome's high complexity CLIA lab for testing. Results are posted on a secure portal for the clinician and patient in one to two weeks, so that health professionals and patients can review the results together.
Dr. Ed Zuckerberg DDS FAGD, Chief Dental Officer at Viome, highlights the transformative impact of Viome's test and Henry Schein's unique ability to help generate greater access across healthcare. "The traditional approach to oral care has been predominantly reliant on visual and tactile examinations. With new research and technology, we can now better understand the risks for oral health diseases and better detect the onset of oral and throat cancer. Oral Health Pro With CancerDetect can help change oral healthcare for both patients and medical professionals who never had access to this type of test. Our collaboration with Henry Schein extends the power of preventive care and it enables dentists and medical professionals to be more effective in their treatments, fundamentally changing the game."
According to Nutrients, an international, peer-reviewed, open access journal of human nutrition, there are over 400,000 new cases of oral cancer reported annually in the
"At Henry Schein, we are pleased to deliver the first crucial step in Viome's process for detecting biomarkers associated with oral or throat cancer, marking a significant advancement for Henry Schein's product offerings and dentistry at large in helping to prevent cancer," said Dr. Bruce Lieberthal, Vice President and Chief Innovation Officer at Henry Schein. "Understanding the importance of early detection and intervention, we're pleased to be able to work with Viome to enhance patient outcomes and usher in a new era for dental and medical professionals. Our vision is to help lead a transformation where oral care prioritizes prevention, focusing on the patient's health and well-being in and outside dental and medical offices. This is a pivotal step in redefining the current standard of care, where early action and prevention lead to a healthier society."
For more information please visit http://viomepro.com and https://www.henryschein.com/.
* Viome's Oral Health Pro™ With CancerDetect™ is a laboratory developed test that was validated, pursuant to the Clinical Laboratory Improvements Amendments of 1988 (CLIA), and as such it has not been reviewed by FDA. As with any test, there may be false positives or false negatives.
About Viome
Viome is a pioneering longevity and preventive healthcare company committed to bridging the gap between scientific breakthroughs and their practical implementation as health solutions. Utilizing cutting-edge AI and the world's largest gene expression database, Viome's home-based tests offer individuals personalized nutritional guidance and innovative microbiome health products to enhance lifespan and health.
Viome has empowered over half a million users with its unique approach that marries groundbreaking proprietary RNA sequencing methods with AI technology. This combination analyzes epigenetic biomarkers, providing robust, AI-driven health insights that contribute significantly to promoting a healthy lifespan.
With its top-tier precision nutrition recommendations, Viome offers a comprehensive and personalized solution to aging - at its optimum. This is more than just health optimization; it's a revolution in understanding how we age and enabling us to do so with vitality and wellness.
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for healthcare professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions support dental laboratories, government and institutional health care clinics, and other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein private-brand products in stock.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.
View original content to download multimedia:https://www.prnewswire.com/news-releases/viome-is-partnering-with-henry-schein-to-provide-better-access-to-oral-health-pro-with-cancerdetect-302105911.html
SOURCE Viome
FAQ
What is Viome partnering with Henry Schein for?
What does Viome's laboratory-developed test help with?
What is the process for ordering Oral Health Pro™ With CancerDetect™?
How many new cases of oral cancer are reported annually in the U.S.?
Is Viome's Oral Health Pro™ With CancerDetect™ FDA-approved?
Who is the Chief Dental Officer at Viome?
What is Dr. Bruce Lieberthal's role at Henry Schein?
Where can more information about Viome and Henry Schein be found?
